Connor, Clark & Lunn Investment Management (CC&L)’s Arbutus Biopharma ABUS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$624K	Buy	130,023 +104,164	+403%	+$457K	﹤0.01%	1324
2026 Q1	$116K	Buy	+25,859	New	+$113K	﹤0.01%	1502
2024 Q2	–	Sell	-13,268	Closed	-$34.2K	–	1347
2024 Q1	$34.2K	Buy	+13,268	New	+$34.4K	﹤0.01%	1492
2022 Q4	–	Sell	-90,497	Closed	-$173K	–	1179
2022 Q3	$173K	Buy	+90,497	New	+$213K	﹤0.01%	1006

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ABUS Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Arbutus Biopharma (ABUS) stake by 403% in Q2 2026, buying an estimated $457K and bringing the position to 130,023 shares worth $624K. The position accounts for ﹤0.01% of the portfolio, ranked #1324.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ABUS in Q3 2022 and has held it in 4 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 130,023 shares of Arbutus Biopharma worth $624K as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 104,164 Arbutus Biopharma shares in Q2 2026, an estimated $457K.
Arbutus Biopharma made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1324 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Arbutus Biopharma in Q3 2022 and has held it in 4 quarters since.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.